Clinical Trial to Assess Use of a New Meningitis Vaccine (MenABCWY) in Participants Aged 10 to 25 Years.  A Phase 3, Randomized, Active-Controlled, Observer-Blinded Study to Assess the
Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 When Administered as a 2-dose Regimen and a First-in-Human Study to Describe the Immunogenicity, Safety, and Tolerability of a Bivalent rLP2086–Containing Pentavalent Vaccine (MenABCWY) in Healthy Subjects ≥10 to <26 Years Of Age.